Literature DB >> 1394812

A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer--intravesical thio-TEPA versus oral UFT.

Y Hirao1, E Okajima, S Ozono, S Samma, K Sasaki, T Hiramatsu, K Babaya, S Watanabe, Y Maruyama.   

Abstract

The long-term prophylactic effect of chemotherapy following transurethral electroresection of bladder tumors (TUR-Bt) was investigated using three different modalities: no prophylactic treatment (group C); oral UFT given at 1296 mg/day for 2 years (group U); and intravesical thio-TEPA at 30 mg/30 ml physiological saline, instilled 32 times over 2 years (group T). Patients newly diagnosed as having superficial bladder cancer (stage, less than or equal to pT1b; grade, less than or equal to G2) who had undergone TUR-Bt at Nara Medical University and its affiliated hospitals between November 1986 and March 1990 were allocated to one of the three groups by the envelope method. The initial treatment was maintained until the third recurrence or disease progression, except for TUR-Bt which was performed at the time of recurrence. The registered cases included 51 patients in group C, 50 in group U, and 52 in group T, and the number of evaluable cases in each group were 48, 47, and 45, respectively. The non-recurrence rates at 3 years were 54% in group C, 67% in group U, and 85% in group T, and the difference between groups T and C was significant. In terms of the tumor grade and stage, No significant difference was observed among the groups in the category of G1 or Ta tumors, but the non-recurrence rates determined in group T for G2 or T1 tumors were significantly higher than those obtained in group C. Moreover, no significant difference was found among the groups in relation to solitary tumors, but the non-recurrence rate obtained in group T for multiple tumors was significantly higher than that determined in group C. The overall cumulative recurrence rate in each group was 3.07 in group C, 1.95 in group U, and 0.70 in group T, and that determined according to tumor grade, stage, and multiplicity was also highest in group C, followed by group U and group T. The main adverse effects encountered were upper gastrointestinal (GI) symptoms (8.5%) in group U and irritable bladder (11.1%) in group T. Intravesical instillation of thio-TEPA tended to produce greater preventive efficacy than did oral UFT during the early postoperative period, but the prophylactic efficacy of thio-TEPA and UFT should be elucidated over a longer observation period.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1394812     DOI: 10.1007/bf00686937

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

1.  Thiotepa in the treatment of tumours of the bladder.

Authors:  H C JONES; J SWINNEY
Journal:  Lancet       Date:  1961-09-16       Impact factor: 79.321

2.  Clinical application of 2,5-DI-O-acetyl- -D-gluca ro- (1-4) (6-3)-dilactone (SLA) to the bladder tumor, with special reference to its effect on frequency of tumor recurrences.

Authors:  T Ichikawa
Journal:  J Urol       Date:  1972-10       Impact factor: 7.450

3.  Prophylactic treatment for superficial bladder cancer following transurethral resection.

Authors:  Y Hirao; E Okajima; S Ohara; S Ozono; T Hiramatsu; K Yoshida; K Yamada; H Aoyama; M Hashimoto; S Watanabe
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Prevention of recurrent superficial bladder tumors by oral etretinate: preliminary results of a randomized, double blind multicenter trial in Switzerland.

Authors:  U E Studer; C Biedermann; D Chollet; P Karrer; R Kraft; H Toggenburg; F Vonbank
Journal:  J Urol       Date:  1984-01       Impact factor: 7.450

Review 5.  Rationale for intensive intravesical chemotherapy for superficial bladder cancer.

Authors:  M S Soloway
Journal:  J Urol       Date:  1980-04       Impact factor: 7.450

6.  Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group.

Authors:  H Akaza; S Isaka; K Koiso; T Kotake; T Machida; A Maru; Y Matsumura; T Niijima; K Obata; H Ohe
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 7.  Evaluation and management of patients with superficial bladder cancer.

Authors:  M S Soloway
Journal:  Urol Clin North Am       Date:  1987-11       Impact factor: 2.241

8.  Mitomycin C bladder instillation therapy for bladder tumors.

Authors:  T Mishina; K Oda; S Murata; H Ooe; Y Mori
Journal:  J Urol       Date:  1975-08       Impact factor: 7.450

9.  Effects of single chemotherapeutic agents on development of urinary bladder tumor induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) in rats.

Authors:  K Babaya; S Takahashi; H Momose; H Matsuki; K Sasaki; S Samma; S Ozono; Y Hirao; E Okajima
Journal:  Urol Res       Date:  1987

10.  Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial.

Authors:  H Zincke; D C Utz; W F Taylor; R P Myers; F J Leary
Journal:  J Urol       Date:  1983-03       Impact factor: 7.450

View more
  3 in total

1.  A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin.

Authors:  T Shuin; Y Kubota; S Noguchi; M Hosaka; T Miura; I Kondo; S Fukushima; E Ishizuka; A Furuhata; M Moriyama
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 2.  Active surveillance for nonmuscle invasive bladder cancer.

Authors:  Makito Miyake; Kiyohide Fujimoto; Yoshihiko Hirao
Journal:  Investig Clin Urol       Date:  2016-05-27

Review 3.  Emerging intravesical therapies for management of nonmuscle invasive bladder cancer.

Authors:  Jeffrey J Tomaszewski; Marc C Smaldone
Journal:  Open Access J Urol       Date:  2010-05-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.